DavidFClaxtonMD

Oncology • Hershey, PA

Professor, Medicine, Pennsylvania State University College of Medicine

Join to view full profile

Dr. Claxton is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Claxton's full profile

Already have an account?

Office
500 University Dr
Hershey, PA 17033
Phone+1 717-531-6585

Fax+1 717-531-0429

Summary

I am Board Certified in Internal Medicine. My historical practice was Malignant Hematology - particularly Leukemia. I have an active translational lab and conduct laboratory research.

Education & Training

University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1987 - 1990
McGill University Faculty of MedicineClass of 1978

Certifications & Licensure

PA State Medical License 2000 - 2024
TX State Medical License 1990 - 2003
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly
America's Top Doctors for Cancer Castle Connolly

Clinical Trials

Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Start of enrollment: 2006 Aug 01
Completed
Phase 2
Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients Start of enrollment: 2007 Dec 01
Completed
Phase 2
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation Start of enrollment: 2007 May 01
Terminated
Phase 1, Phase 2
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia Start of enrollment: 2009 Sep 01
Active, not recruiting
Phase 2
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
JVRS-100 for the Treatment of Patients With Relapsed or Refractory Leukemia Start of enrollment: 2009 Mar 01
Completed
Phase 1
Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias Start of enrollment: 2009 Mar 01
Terminated
Phase 1
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia Start of enrollment: 2011 Apr 27
Terminated
Phase 2
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnos Start of enrollment: 2011 Jan 01
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib Start of enrollment: 2010 Nov 01
Completed
Phase 4
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Dec 14
Completed
Phase 2
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Completed
Phase 3
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Start of enrollment: 2014 May 19
Active, not recruiting
Phase 3
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04
Active, not recruiting
Phase 3
Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
No longer available
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia Start of enrollment: 2019 Dec 06
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Sensitivity and Specificity of Chimerism Tests in Predicting Leukemia Relapse Using Increasing Mixed Chimerism.
Ruoheng Zhang, Yimeng Shang, Joseph Cioccio, Kevin Rakszawski, Myles Nickolich
The Journal of Molecular Diagnostics. 2024-12-01
Recurrent disease after a matched sibling hematopoietic transplant in an aplastic anemia patient with a disease risk allele, HLA-B*40:02.
Akshita Khosla, Yoshitaka Inoue, Joseph Cioccio, Kevin Rakszawski, Natthapol Songdej
Blood Transfusion = Trasfusione Del Sangue. 2024-11-01
From Deworming to Cancer Therapy: Benzimidazoles in Hematological Malignancies.
Upendarrao Golla, Satyam Patel, Nyah Shah, Stella Talamo, Riya Bhalodia
Cancers. 2024-10-12

Journal Articles

Clofarabine Followed by Haploidentical Stem Cell Transplant Using Fludarabine, Busulfan, and Total-Body Irradiation with Post-Transplant Cyclophosphamide in Non-Remiss...
Shin Mineishi, David Claxton, Kevin Rakszawski, Hiroko Shike, International Journal of Hematology

Abstracts/Posters

Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Resul...
David F. Claxton, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Effect of Avelumab to Immune Response in AML: A Phase I Study of Avelumab in Combination with Decitabine As First Line Treatment of Unfit Patients
David F. Claxton, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particular...
David F. Claxton, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Tr...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
The Novel Small Molecule Inhibitor KS99 Targets AML and Inhibits Stemness Markers STAT3 and ALDH
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Multi-Dimensional Analysis of Immune Signature Predicts Response to Decitabine Treatment in Elderly Patients with AML
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Woman Shares Rock Solid HopeSeptember 28th, 2016

Grant Support

Autologous Anti-Cml ImmunityNational Cancer Institute1998–2002
Core Binding Factor In Leukemogenesis--Inv(16) And T(8;21)National Cancer Institute1996–2001